High-potency oral solid dosage (OSD) formulations are becoming increasingly important as pharmaceutical pipelines move toward targeted oncology therapies, immunosuppressants, hormonal products, and other drugs that deliver therapeutic effects at very low doses.
For these products, choosing a CDMO is not simply about tablet or capsule manufacturing capacity. Sponsors need high-containment facilities, occupational exposure limit (OEL) controls, specialized formulation technologies, analytical capabilities, cleaning validation, safe scale-up, and regulatory experience.
Understand What Companies Are Investing In And What Customers Are Willing To Buy. Download Sample: https://www.towardshealthcare.com/download-sample/5341
The leading CDMOs in this space include Lonza, Catalent, CordenPharma, Aenova, Recipharm, Siegfried, and Piramal Pharma Solutions.
What makes high-potency OSD manufacturing different?
High-potency APIs can require extremely low exposure limits and specialized containment throughout dispensing, blending, granulation, compression, coating, encapsulation, packaging and cleaning.
This makes technologies such as isolators, barrier systems, contained transfer, micronization, roller compaction, spray drying, hot-melt extrusion and specialized capsule filling particularly important.
The strongest CDMOs therefore offer more than conventional tablet production. They connect HPAPI handling + formulation development + OSD manufacturing + analytical testing + clinical supply + commercial production.
Top High-Potency OSD CDMOs
1. Lonza
Lonza is one of the strongest options for sponsors looking for an integrated HPAPI-to-drug-product platform.
The company reports more than 30 years of HPAPI experience, scalability from laboratory development to 10,000-liter API manufacturing, and containment capability down to 1 ng/m³ for HPAPI manufacturing.
Its drug-product network includes specialized technologies for low-dose oral solids, API powder encapsulation, micronization, jet milling and spray drying.
Lonza has also invested heavily in its U.S. oral drug-product capabilities. Its Tampa site received more than $15 million of investment over two years, including new product-development suites, a sampling and dispensing suite and high-containment roller-compaction equipment.
This makes Lonza particularly relevant for:
- Oncology HPAPIs
- Very-low-dose formulations
- Poorly soluble molecules
- Complex oral formulations
- Clinical-to-commercial programs
- Sponsors seeking API and drug-product integration
2. Catalent
Catalent is another major choice for high-potency OSD programs because of the breadth of its global drug-product network.
Catalent reports 20+ years of potent-compound experience and more than 300 Category 3 and Category 4 compounds managed across 12 sites.
Its HPAPI drug-product platform includes tablets, capsules, orally disintegrating tablets and softgels.
Catalent also uses dedicated isolators and validated containment systems for highly potent compounds, including compounds handled at nanogram-level OELs.
Its capabilities include:
- Tablet manufacturing
- Capsule filling
- ODT manufacturing
- Softgels
- Spray drying
- Micronization
- Particle engineering
- Analytical development
- Cleaning validation
- Clinical and commercial manufacturing
Catalent is particularly attractive for companies that need multiple dosage-form options within one CDMO network.
3. CordenPharma
CordenPharma is particularly strong when the requirement is high-potency and oncology-focused OSD manufacturing.
Its Plankstadt, Germany facility supports commercial OSD batches ranging from approximately 1 kg to 300 kg, while its high-potency platform supports OSD production from laboratory-scale formulations through commercial manufacturing.
CordenPharma reports dedicated containment areas capable of handling HPAPIs at OEL levels below 0.05 µg/m³.
Its OSD technologies include:
- Tablets
- Mini-tablets
- Hard gelatin capsules
- HPMC capsules
- Powders
- Granules
- Pellets
- Immediate-release formulations
- Modified-release formulations
- Roller compaction
- High-shear granulation
- Fluid-bed granulation
- Hot-melt extrusion
- Spray drying
- Micronization
- Nanomilling
CordenPharma also invested approximately €10 million in a new GMP Clinical Trial Development facility at Plankstadt, designed to manufacture batches up to 60 kg and bridge the gap between small-scale development and commercial manufacturing.
Its Boulder facilities also have a combined API and peptide capacity approaching 500,000 liters, providing an additional drug-substance platform for integrated programs.
4. Aenova
Aenova stands out for its large-scale oral-solids manufacturing footprint.
The company reports 9 oral-solids manufacturing sites, 5 development centers, more than 22 billion tablets and capsules of annual capacity, and more than 170 scientists and analysts dedicated to development services.
Its network includes dedicated high-potency capabilities.
Regensburg in Germany functions as a competence center for development and manufacturing of oral solid dosage forms containing high-potency APIs, while Marburg focuses on oncology and high-potency solid products.
Aenova’s capabilities cover:
- Tablets
- Capsules
- Modified-release products
- Oncology formulations
- High-potency APIs
- Hormonal products
- Hot-melt extrusion
- Complex solid dosage forms
- Packaging
- Clinical supply
- Commercial manufacturing
Its historical network data also reports solid-dose manufacturing capabilities up to OEB 5, making Aenova particularly relevant for potent and low-dose products.
5. Recipharm
Recipharm has built a dedicated position around high-potency OSD manufacturing from clinical development through commercial supply.
Its high-potency OSD platform emphasizes risk assessment across the entire manufacturing process, including sampling, dispensing, manufacturing, packaging, analysis, cleaning and waste handling.
The company supports:
- Powders
- Granules
- Pellets
- Tablets
- Capsules
- Immediate-release products
- Modified-release products
- High-potency formulations
Recipharm has also expanded its high-potency capabilities and oral-product development infrastructure in response to growing demand for complex oral medicines.
Its footprint across Europe, the U.S. and Asia can also be valuable for companies seeking regional manufacturing and supply-chain options.
6. Siegfried
Siegfried combines API development and manufacturing with finished drug-product capabilities, which can be valuable for complex HPAPI programs.
The company reports more than 30 years of experience in complex OSD projects, including highly potent products and modified-release formulations.
Its drug-product network supports:
- Highly potent tablets
- Highly potent capsules
- Hard capsules
- Pellets
- Mini-tablets
- Film-coated tablets
- Modified-release products
- Inhalation capsules
Siegfried reports containment capability reaching OEL levels as low as 0.1 µg/m³ in its drug-product operations.
Its Barberà del Vallès site in Spain specifically supports high-potency OSD manufacturing and packaging and has 479 employees, according to the company’s current site information.
7. Piramal Pharma Solutions
Piramal Pharma Solutions is particularly important for companies seeking large-volume OSD manufacturing combined with high-potency formulation capabilities.
Its Pithampur, India facility has reported total OSD capacity of approximately 4.5 billion units per year, with batch sizes ranging from 4 kg to 600 kg.
The site supports:
- Immediate-release tablets
- Modified-release tablets
- Capsules
- Wet granulation
- Dry granulation
- Roller compaction
- Fluid-bed processing
- Film coating
- Bilayer compression
- Bottle packaging
- Blister packaging
Piramal also reports dedicated capabilities for potent oral solid formulations, with OEL capability above 1 µg/m³, while its Sellersville, Pennsylvania facility supports highly potent formulations down to 1 µg/m³.
Its Pithampur expansion was supported by an approximately $11 million investment, increasing site capacity from 3 billion to 4.5 billion doses.
High-Potency OSD CDMO Comparison
| CDMO | Key high-potency statistic | OSD capability | Scale / footprint indicator | Particularly relevant for |
|---|---|---|---|---|
| Lonza | Containment down to 1 ng/m³ | Low-dose oral solids, capsules, particle engineering | HPAPI scale from lab to 10,000 L | Ultra-potent and complex HPAPI programs |
| Catalent | 300+ Category 3/4 compounds across 12 sites | Tablets, capsules, ODTs, softgels | 12 potent-compound sites | Multi-format global programs |
| CordenPharma | OEL below 0.05 µg/m³ | Tablets, capsules, pellets, mini-tablets | Commercial batches up to 300 kg | Oncology and high-potency OSD |
| Aenova | Capabilities up to OEB 5 | Tablets, capsules, modified release, oncology | 22B+ tablets/capsules annually | Large-scale solid-dose programs |
| Recipharm | High-potency containment infrastructure | Tablets, capsules, pellets, granules | Europe, U.S. and Asia footprint | Clinical-to-commercial HP OSD |
| Siegfried | OEL down to 0.1 µg/m³ | High-potency tablets/capsules, pellets | 6 drug-product sites globally | Complex OSD and HPAPI programs |
| Piramal Pharma Solutions | Potent OSD capability around 1 µg/m³ at key sites | Tablets, capsules, MR/IR, specialty OSD | 4.5B OSD units/year at Pithampur | High-volume commercial OSD |
Published company figures are not directly comparable because CDMOs report different OEL/OEB definitions, site scopes, capacities and manufacturing stages.
Which CDMO Is Best for High-Potency OSD?
There is no single best CDMO for every HPAPI program.
The right selection depends on the molecule’s potency, OEL/OEB classification, dose, solubility, formulation complexity, batch size, clinical stage, containment requirements and commercial volume.
Best for ultra-potent HPAPI and integrated development
Lonza is particularly strong where the sponsor needs integrated HPAPI development, particle engineering and specialized oral drug-product manufacturing.
Best for broad dosage-form flexibility
Catalent is attractive for programs that may move between tablets, capsules, ODTs and softgels and require a broad global network.
Best for oncology-focused high-potency OSD
CordenPharma has a particularly strong positioning in high-potency and oncology OSD, with published containment capabilities below 0.05 µg/m³ and commercial OSD batch sizes up to 300 kg.
Best for large-scale oral solids
Aenova stands out for its more than 22 billion annual tablet and capsule capacity, combined with dedicated high-potency and oncology sites.
Best for high-volume OSD plus cost-efficient manufacturing
Piramal Pharma Solutions is particularly relevant when commercial volume is a major consideration, with Pithampur’s 4.5 billion-unit annual OSD capacity.
What Pharma Companies Should Evaluate Before Selecting a CDMO
For a high-potency OSD program, procurement teams should evaluate more than quoted manufacturing cost.
Key criteria include:
Containment
What is the CDMO’s validated OEL/OEB capability for the specific compound?
Formulation technology
Can the site handle roller compaction, high-shear granulation, fluid-bed processing, spray drying, HME, micronization or nanomilling?
Scale-up
Can the same partner move the product from formulation development to Phase I, Phase II, Phase III and commercial manufacturing?
Cross-contamination control
What isolators, air-handling systems, cleaning validation and material-transfer controls are available?
Analytical capability
Can the CDMO perform potency, content uniformity, dissolution, impurity, stability and cleaning-validation studies in-house?
Regulatory experience
Has the facility been inspected or approved by agencies relevant to the target markets?
Commercial capacity
Is sufficient capacity available when the product reaches launch?
Technology transfer
Can the CDMO accept an existing formulation and transfer it into a contained manufacturing environment without significant process disruption?
Buyer Identification
The main buyers of high-potency OSD CDMO services include:
- Pharmaceutical companies developing oncology and targeted therapies
- Biotech companies advancing Phase I to Phase III HPAPI programs
- Specialty pharma companies commercializing low-volume, high-value medicines
- Generic drug manufacturers developing high-potency generic products
- NCE developers requiring formulation and clinical supply
- Virtual pharma companies outsourcing most manufacturing operations
- Companies developing lifecycle-management formulations
- Sponsors developing modified-release or low-dose products
Within these companies, purchasing decisions are typically influenced by:
- CMC leaders
- Formulation scientists
- Drug-product development teams
- Manufacturing and MSAT teams
- Quality and regulatory teams
- Procurement and sourcing
- Supply-chain leadership
- Commercial operations
The Competitive Landscape Is Becoming More Specialized
The high-potency OSD CDMO market is moving away from a simple “tablet manufacturer” model.
The competitive advantage increasingly comes from the ability to connect:
HPAPI → containment → formulation → particle engineering → OSD manufacturing → analytical development → clinical supply → commercial production
This is particularly important for oncology pipelines, where potent molecules can require extremely low exposure limits and specialized handling.
CDMOs with both drug-substance and drug-product capabilities can also reduce the number of technology-transfer points between API manufacturing and finished-dose production.
How Towards Healthcare Research & Consulting Can Help
Towards Healthcare Research & Consulting can help pharma and biotech companies build a data-driven view of the high-potency OSD CDMO landscape.
Our analysis can track:
- CDMO manufacturing capacity
- HPAPI containment capabilities
- OEL/OEB classifications
- Tablet and capsule production capacity
- High-potency facility investments
- New manufacturing expansions
- Clinical and commercial programs
- CDMO partnerships
- Technology platforms
- Oncology and specialty-pharma pipelines
- Regional manufacturing footprints
- Competitor benchmarking
The key question is no longer simply:
“Which CDMO can manufacture our tablets?”
It is:
“Which CDMO has the containment, formulation technology, capacity and regulatory infrastructure to take our high-potency molecule from development to commercial scale?”
For pharma and biotech companies developing HPAPI-based oral products, that distinction can materially affect development timelines, manufacturing risk, commercial scalability and supply security.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium